These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 24951378)

  • 1. [Impact of serum Anti-Mullerian Hormone levels on the results of assisted reproductive technologies. Single-center retrospective study from 2011 cycles (ICSI and bilateral tubal obstruction excluded)].
    Dosso N; Robin G; Catteau-Jonard S; Pigny P; Leroy-Billiard M; Dewailly D
    J Gynecol Obstet Biol Reprod (Paris); 2015 Jan; 44(1):63-71. PubMed ID: 24951378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(18):1-63. PubMed ID: 23074488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using serum anti-Müllerian hormone levels to predict the chance of live birth after spontaneous or assisted conception: a systematic review and meta-analysis.
    Peigné M; Bernard V; Dijols L; Creux H; Robin G; Hocké C; Grynberg M; Dewailly D; Sonigo C
    Hum Reprod; 2023 Sep; 38(9):1789-1806. PubMed ID: 37475164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of in vitro fertilization versus intrauterine insemination in patients with low anti-Müllerian hormone levels. A single-center retrospective study of 639 + 119 cycles.
    Sapet C; Gavoille A; Sesques A; Freour T; Subtil F; Salle B
    J Gynecol Obstet Hum Reprod; 2021 Mar; 50(3):101874. PubMed ID: 32687891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of Anti-Müllerian hormone in low and extremely low ovarian reserve in relation to live birth after in vitro fertilization.
    Reijnders IF; Nelen WL; IntHout J; van Herwaarden AE; Braat DD; Fleischer K
    Eur J Obstet Gynecol Reprod Biol; 2016 May; 200():45-50. PubMed ID: 26967346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What are the likely IVF/ICSI outcomes if there is a discrepancy between serum AMH and FSH levels? A multicenter retrospective study.
    Daney de Marcillac F; Pinton A; Guillaume A; Sagot P; Pirrello O; Rongieres C
    J Gynecol Obstet Hum Reprod; 2017 Oct; 46(8):629-635. PubMed ID: 28843783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve.
    Oriol B; Barrio A; Pacheco A; Serna J; Zuzuarregui JL; Garcia-Velasco JA
    Fertil Steril; 2008 Nov; 90(5):1579-82. PubMed ID: 18054933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles.
    La Marca A; Minasi MG; Sighinolfi G; Greco P; Argento C; Grisendi V; Fiorentino F; Greco E
    Fertil Steril; 2017 Nov; 108(5):777-783.e2. PubMed ID: 28987789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of serum anti-Mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle.
    Lin PY; Huang FJ; Kung FT; Chiang HJ; Lin YJ; Lin YC; Lan KC
    Int J Clin Exp Pathol; 2014; 7(9):6245-53. PubMed ID: 25337276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive values of anti-müllerian hormone, antral follicle count and ovarian response prediction index (ORPI) for assisted reproductive technology outcomes.
    Ashrafi M; Hemat M; Arabipoor A; Salman Yazdi R; Bahman-Abadi A; Cheraghi R
    J Obstet Gynaecol; 2017 Jan; 37(1):82-88. PubMed ID: 27976974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of anti-Müllerian hormone-tailored ovarian stimulation protocols in in vitro fertilization/intracytoplasmic sperm injection cycles in women of advanced age.
    Liao CC; Lee RK; Lin SY; Lin MH; Hwu YM
    Taiwan J Obstet Gynecol; 2016 Apr; 55(2):239-43. PubMed ID: 27125408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes.
    Styer AK; Gaskins AJ; Brady PC; Sluss PM; Chavarro JE; Hauser RB; Toth TL
    Fertil Steril; 2015 Nov; 104(5):1153-61.e1-7. PubMed ID: 26315051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection.
    Wunder DM; Guibourdenche J; Birkhäuser MH; Bersinger NA
    Fertil Steril; 2008 Dec; 90(6):2203-10. PubMed ID: 18291376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between anti-müllerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes.
    Cupisti S; Dittrich R; Mueller A; Strick R; Stiegler E; Binder H; Beckmann MW; Strissel P
    Eur J Med Res; 2007 Dec; 12(12):604-8. PubMed ID: 18024272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance between day-3 follicle stimulating hormone & anti-Müllerian hormone is predictive of clinical pregnancy during fertility treatment.
    Butler WJ; Pico A; Hawkins KC; Younis AI
    Gynecol Endocrinol; 2021 Sep; 37(9):798-801. PubMed ID: 33355011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of repetitive oocyte retrieval on the ovarian reserve: a retrospective cohort study.
    Marschalek J; Ott J; Aitzetmueller M; Mayrhofer D; Weghofer A; Nouri K; Walch K
    Arch Gynecol Obstet; 2019 May; 299(5):1495-1500. PubMed ID: 30790103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.
    Nelson SM; Klein BM; Arce JC
    Fertil Steril; 2015 Apr; 103(4):923-930.e1. PubMed ID: 25624196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.